GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hinova Pharmaceuticals Inc (SHSE:688302) » Definitions » Additional Paid-In Capital

Hinova Pharmaceuticals (SHSE:688302) Additional Paid-In Capital : ¥0.00 Mil(As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Hinova Pharmaceuticals Additional Paid-In Capital?


Hinova Pharmaceuticals's quarterly additional paid-in capital increased from Mar. 2024 (¥0.00 Mil) to Jun. 2024 (¥2,564.70 Mil) but then stayed the same from Jun. 2024 (¥2,564.70 Mil) to Sep. 2024 (¥0.00 Mil).

Hinova Pharmaceuticals's annual additional paid-in capital increased from Dec. 2021 (¥1,327.04 Mil) to Dec. 2022 (¥2,310.03 Mil) and increased from Dec. 2022 (¥2,310.03 Mil) to Dec. 2023 (¥2,509.89 Mil).

Hinova Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Hinova Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hinova Pharmaceuticals Additional Paid-In Capital Chart

Hinova Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial 62.70 1,288.32 1,327.04 2,310.03 2,509.89

Hinova Pharmaceuticals Quarterly Data
Dec18 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 2,509.89 - 2,564.70 -

Hinova Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Hinova Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Hinova Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Hinova Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hinova Pharmaceuticals Inc (SHSE:688302) » Definitions » Additional Paid-In Capital
Comparable Companies
BJSE:833575 SZSE:300149 SZSE:301230 SHSE:688221 SZSE:003020 SHSE:688136 SZSE:300942 SZSE:300204 SHSE:688670 SZSE:300381 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
No. 5 Keyuan South Road, No. 2 and 3, 4th Floor, Building 1, Rongyao Building, High-tech Zone, Sichuan Province, Chengdu, CHN, 610041
Website
http://www.hinovapharma.com
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.

Hinova Pharmaceuticals Headlines

No Headlines